23 hours Ago By Defense World Staff
Renaissance Technologies LLC decreased its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 13.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).
The fund owned 554,541 shares of the company’s stock after selling 87,468 shares during the quarter. Renaissance Technologies LLC owned about 0.26% of Allogene Therapeutics worth $1,181,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in ALLO. Cibc World Markets Corp bought a new position in Allogene Therapeutics in the fourth quarter valued at approximately $26,000. PAX Financial Group LLC acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at approximately $27,000.
RPO LLC acquired a new position in shares of Allogene Therapeutics in the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS bought a new position in Allogene Therapeutics in the 4th quarter valued at about $43,000. Finally, Teacher Retirement System of Texas lifted its holdings in Allogene Therapeutics by 28.
9% during the 4th quarter. Teacher Retirement System of Texas now owns 43,877 shares of the company’s stock worth $93,000 after purchasing an additional 9,839 shares during the last quarter. Institutional investors and hedge funds own 83.
63% of the company’s stock. Insider Buying and SellingIn other news, CEO David D. Chang sold 46,668 shares of the company’s stock in a transaction that occurred on Friday, March 14th.
The stock was sold at an average price of $1.96, for a total transaction of $91,469.28.
Following the transaction, the chief executive officer now directly owns 5,276,569 shares of the company’s stock, valued at $10,342,075.24. This represents a 0.
88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy L.
Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.
66. Following the completion of the sale, the insider now directly owns 250,713 shares of the company’s stock, valued at approximately $428,719.23.
The trade was a 5.55 % decrease in their position. The disclosure for this sale can be found here.
In the last three months, insiders have sold 87,268 shares of company stock valued at $159,584. 24.30% of the stock is owned by company insiders.
Analyst Upgrades and DowngradesSeveral research analysts have recently commented on ALLO shares. HC Wainwright lowered their target price on shares of Allogene Therapeutics from $9.00 to $8.
00 and set a “buy” rating on the stock in a report on Wednesday, March 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of Allogene Therapeutics in a research report on Friday, March 14th.
Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research note on Friday, March 14th. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.
00 price target for the company in a research note on Friday, March 14th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.
com, Allogene Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $9.29.Check Out Our Latest Stock Report on Allogene TherapeuticsAllogene Therapeutics Stock PerformanceShares of ALLO opened at $1.
54 on Wednesday. The business’s 50 day moving average price is $1.67 and its two-hundred day moving average price is $2.
04. The firm has a market cap of $334.59 million, a PE ratio of -0.
99 and a beta of 0.99. Allogene Therapeutics, Inc.
has a 52-week low of $1.23 and a 52-week high of $3.78.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.
34) by $0.06. Research analysts predict that Allogene Therapeutics, Inc.
will post -1.28 EPS for the current fiscal year. Allogene Therapeutics Company Profile (Free Report)Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.
It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).See AlsoFive stocks we like better than Allogene TherapeuticsWhat is a Special Dividend?Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetHow to Short a Stock in 5 Easy Steps Coca-Cola Company Stock Can Bubble to New Highs This YearConsumer Discretionary Stocks Explained3 Stocks Lifting 2025 Guidance Despite Market Jitters.
